1993
DOI: 10.1016/0002-9149(93)90905-r
|View full text |Cite
|
Sign up to set email alerts
|

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
63
0

Year Published

1999
1999
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 155 publications
(64 citation statements)
references
References 24 publications
0
63
0
Order By: Relevance
“…The design and rationale of the BIP Registry and study were published previously 25, 26. Of the 15 524 screened patients, only 3090 (20%) were randomized in the prospective interventional 6‐year BIP study that compared bezafibrate with placebo.…”
Section: Methodsmentioning
confidence: 99%
“…The design and rationale of the BIP Registry and study were published previously 25, 26. Of the 15 524 screened patients, only 3090 (20%) were randomized in the prospective interventional 6‐year BIP study that compared bezafibrate with placebo.…”
Section: Methodsmentioning
confidence: 99%
“…The design and rationale of the BIP study have been published previously. 9,10 The BIP registry patients had a diagnosis of CHD established by: (1) a history of myocardial infarction (MI) occurring no less than 6 months but no longer than 5 years prior to enrollment; (2) stable angina pectoris, which was symptomatic and documented on nuclear study/exercise test/coronary angiography (demonstrating a stenosis of above or equal to 60 % in one of the major coronary arteries); (3) primary transcutaneous coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG) operation in the 6 months prior to enrollment.…”
Section: Introductionmentioning
confidence: 99%
“…13 The BIP study was designed and initiated in 1990. There was no difference in the distribution of all-cause and cardiac mortality between the bezafibrate and placebo study groups.…”
Section: Subjectsmentioning
confidence: 99%
“…14 The major inclusion and exclusion criteria for the BIP study, as well as the ethical guidelines, have been previously reported. 13,14 In brief, between 1 February 1990, and 30 October 1992 all patients underwent a complete medical examination and biochemical blood tests; historical, medical, and drug intake data were recorded. The major exclusion criteria for the BIP study were: permanent pacemaker implantation, cerebrovascular disease, chronic hepatic or renal disease, peripheral vascular disease, malignant diseases, estrogen replacement therapy and insulin dependent diabetes mellitus.…”
Section: Subjectsmentioning
confidence: 99%